Boehringer and MD Anderson extend KRAS cancer collaborationBoehringer Ingelheim and The University of Texas MD Anderson Cancer Center have extended and expanded a collaboration exploring Share XBoehringer and MD Anderson extend KRAS cancer collaborationhttps://pharmaphorum.com/news/boehringer-and-md-anderson-extend-kras-cancer-collaboration/
Gilead’s Trodelvy approved in metastatic urothelial cancerGilead’s Trodelvy has another string to its bow after FDA approval in patients with advanced metastatic urothelial cancer. Share XGilead’s Trodelvy approved in metastatic urothelial cancerhttps://pharmaphorum.com/news/gileads-trodelvy-approved-in-metastatic-urothelial-cancer/
AZ aims at Pfizer, GSK with potential new PARP cancer drugAstraZeneca’s Lynparza (olaparib) blazed a trail for the new class of PARP drugs when it was approved in Share XAZ aims at Pfizer, GSK with potential new PARP cancer drughttps://pharmaphorum.com/news/az-aims-at-pfizer-gsk-with-potential-new-parp-cancer-drug/
Merck’s Keytruda demonstrates adjuvant use in kidney cancerMerck & Co has announced interim data from its pivotal Phase 3 KEYNOTE-564 trial evaluating immunotherapy Keytruda for Share XMerck’s Keytruda demonstrates adjuvant use in kidney cancerhttps://pharmaphorum.com/news/mercks-keytruda/
Cancer Research UK spinout Achilles raises $175.5m in IPOUK biotech Achilles Therapeutics has completed its initial public offering (IPO) in the US, raising $175.5 million that Share XCancer Research UK spinout Achilles raises $175.5m in IPOhttps://pharmaphorum.com/news/cancer-research-uk-spinout-achilles-raises-175-5m-in-ipo/
Gilead scores US approval for breast cancer drug that wowed ESMOGilead’s $21 billion purchase of Immunomedics and its potential blockbuster Trodelvy continues to pay off, as the drug Share XGilead scores US approval for breast cancer drug that wowed ESMOhttps://pharmaphorum.com/news/gilead-scores-us-approval-for-breast-cancer-drug-that-wowed-esmo/
Novartis expands in radio-oncology again with $1.3bn Artios allianceIn its second licensing deal in the radio-oncology area in consecutive weeks, Novartis has agreed a $1.3 billion-plus Share XNovartis expands in radio-oncology again with $1.3bn Artios alliancehttps://pharmaphorum.com/news/novartis-expands-in-radio-oncology-again-with-1-3bn-artios-alliance/
Sanofi’s Sarclisa gains new US multiple myeloma indicationThe FDA has approved Sanofi’s Sarclisa (isatuximab) in combination with a new chemotherapy regimen for advanced multiple myeloma, Share XSanofi’s Sarclisa gains new US multiple myeloma indicationhttps://pharmaphorum.com/news/sanofis-sarclisa-gains-new-us-multiple-myeloma-indication/
Pyxis follows Pfizer alliance with $152m fundraising for cancer pipelineFresh from a licensing agreement with Pfizer, US startup Pyxis Oncology has raised a sizeable $152 million in Share XPyxis follows Pfizer alliance with $152m fundraising for cancer pipelinehttps://pharmaphorum.com/news/pyxis-follows-pfizer-alliance-with-152m-fundraising-for-cancer-pipeline/
